Published in Blood Weekly, October 31st, 2002
V.I. Technologies (Vitex) also presented its overall clinical development program for Inactine red blood cells including results of completed clinical trials. Additional study data on the chemistry and safety profile for the Inactine pathogen reduction...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.